DK4197528T3 - Sammensætninger, fremgangsmåder og systemer til indgivelse af medicin med aerosol - Google Patents

Sammensætninger, fremgangsmåder og systemer til indgivelse af medicin med aerosol Download PDF

Info

Publication number
DK4197528T3
DK4197528T3 DK23155432.0T DK23155432T DK4197528T3 DK 4197528 T3 DK4197528 T3 DK 4197528T3 DK 23155432 T DK23155432 T DK 23155432T DK 4197528 T3 DK4197528 T3 DK 4197528T3
Authority
DK
Denmark
Prior art keywords
systems
methods
drug delivery
delivery compositions
aerosol drug
Prior art date
Application number
DK23155432.0T
Other languages
English (en)
Inventor
Vidya Joshi
James Archbell
Kellisa Lachacz
Charina Lampa
Lauren Mello
Gertrude Gutierrez
David Lechuga-Ballesteros
Penny Tan
Michael RIEBE
Original Assignee
Astrazeneca Pharmaceuticals Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Pharmaceuticals Lp filed Critical Astrazeneca Pharmaceuticals Lp
Application granted granted Critical
Publication of DK4197528T3 publication Critical patent/DK4197528T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/16Fluorine compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK23155432.0T 2021-07-09 2022-07-08 Sammensætninger, fremgangsmåder og systemer til indgivelse af medicin med aerosol DK4197528T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163220362P 2021-07-09 2021-07-09
US202163282356P 2021-11-23 2021-11-23
EP22748656.0A EP4175619B1 (en) 2021-07-09 2022-07-08 Compositions, methods and systems for aerosol drug delivery

Publications (1)

Publication Number Publication Date
DK4197528T3 true DK4197528T3 (da) 2024-05-06

Family

ID=82748203

Family Applications (2)

Application Number Title Priority Date Filing Date
DK22748656.0T DK4175619T3 (da) 2021-07-09 2022-07-08 Sammensætninger, fremgangsmåder og systemer til indgivelse af medicin med aerosol
DK23155432.0T DK4197528T3 (da) 2021-07-09 2022-07-08 Sammensætninger, fremgangsmåder og systemer til indgivelse af medicin med aerosol

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK22748656.0T DK4175619T3 (da) 2021-07-09 2022-07-08 Sammensætninger, fremgangsmåder og systemer til indgivelse af medicin med aerosol

Country Status (13)

Country Link
US (1) US20230026203A1 (da)
EP (4) EP4197528B1 (da)
KR (3) KR20240042438A (da)
AU (3) AU2022305962A1 (da)
CA (3) CA3226155A1 (da)
CO (3) CO2024000631A2 (da)
DK (2) DK4175619T3 (da)
DO (3) DOP2024000004A (da)
FI (2) FI4175619T3 (da)
IL (3) IL309888A (da)
PE (2) PE20240807A1 (da)
TW (3) TW202317080A (da)
WO (3) WO2023283441A1 (da)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023212191A1 (en) * 2022-04-28 2023-11-02 Astrazeneca Ab Combination of albuterol and budesonide for the treatment of asthma

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US37872A (en) 1863-03-10 Improved mast-hoop
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
GB1200886A (en) 1966-09-23 1970-08-05 Allen & Hanburys Ltd Phenylaminoethanol derivatives
US3994974A (en) 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
SE378109B (da) 1972-05-19 1975-08-18 Bofors Ab
US4187301A (en) 1978-04-05 1980-02-05 Syntex (U.S.A.) Inc. 17 Beta-thiocarboxylic acid esters of 6 alpha, 6 beta-difluoro-3-oxoandrost-4-enes
JPS56138200A (en) 1980-02-15 1981-10-28 Glaxo Group Ltd Androstane carbothioate compound
ATE8790T1 (de) 1981-02-02 1984-08-15 Schering Corporation Aromatische heterocyclische steroidester, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten.
ZW6584A1 (en) 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
US5707634A (en) 1988-10-05 1998-01-13 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
GB8903593D0 (en) 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
US5610163A (en) 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
AU659645B2 (en) 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
SE9404080L (sv) 1993-12-28 1995-06-29 Ciba Geigy Ag Förfarande för framställning av en optiskt ren enantiomer av formoterol
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
DE4440337A1 (de) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US6309671B1 (en) 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
JP3708553B2 (ja) 1995-04-14 2005-10-19 ネクター セラピューティクス 向上した分散性を有する粉末型薬理組成物
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
US5833891A (en) 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
US5886200A (en) 1996-07-01 1999-03-23 Schering Corporation Process for the preparation of 17-esters of 9 α, 21-dihalo-pregnane-11 β, 17 α-diol-20-ones
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
US6010935A (en) 1997-08-21 2000-01-04 Micron Technology, Inc. Self aligned contacts
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
NZ500555A (en) 1999-08-02 2000-11-24 Hovione Int Ltd Process for the preparation of mometasone furoate
MXPA02004193A (es) 1999-10-29 2002-12-13 Inhale Therapeutic Syst Composiciones de polvo seco que tienen caracteristicas de dispersion mejoradas.
TWI290473B (en) 2000-05-10 2007-12-01 Alliance Pharma Phospholipid-based powders for drug delivery
US6908928B2 (en) 2000-10-12 2005-06-21 Bi Pharma Kg. Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
US7550133B2 (en) * 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
EP1606261B1 (en) 2003-03-10 2009-11-04 Nycomed GmbH Novel process for the preparation of roflumilast
KR20060015316A (ko) 2003-05-28 2006-02-16 넥타르 테라퓨틱스 아미노산 및/또는 인지질로 부분 또는 완전 코팅된수불용성 활성제 미립자의 제조를 위한 알코올성 수용액의분무 건조법
EP1904219A4 (en) 2005-07-15 2011-07-27 Map Pharmaceuticals Inc METHOD FOR FORMING PARTICLES
CN100560598C (zh) 2005-07-26 2009-11-18 上海奥锐特国际贸易有限公司 氟替卡松丙酸酯的合成方法
PL3111926T3 (pl) 2009-05-29 2020-06-29 Pearl Therapeutics, Inc. Kompozycje, sposoby i układy do dostarczania dwóch lub większej liczby środków czynnych do układu oddechowego
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
KR20140032404A (ko) * 2011-05-17 2014-03-14 펄 테라퓨틱스 인코포레이티드 2 개 이상의 활성제의 호흡기 전달을 위한 조성물, 방법 & 시스템
CA2855021A1 (en) 2011-11-09 2013-05-23 Mylan Laboratories Ltd Process for the preparation of roflumilast
WO2013130767A1 (en) * 2012-02-29 2013-09-06 Pulmatrix, Inc. Inhalable dry powders
EP2909177B1 (en) 2012-10-17 2017-03-29 Interquim, S.A. Process for preparing roflumilast
NZ710726A (en) * 2013-01-28 2020-08-28 Incozen Therapeutics Pvt Ltd Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide
MX2015016058A (es) * 2013-05-22 2016-12-20 Pearl Therapeutics Inc Composiciones, metodos y sistemas para el suministro por via respiratoria de tres o mas agentes activos.
US11833292B2 (en) 2017-10-09 2023-12-05 Pearl Therapeutics, Inc. Drug delivery systems and related methods

Also Published As

Publication number Publication date
CA3226155A1 (en) 2023-01-12
IL309908A (en) 2024-03-01
EP4175620A1 (en) 2023-05-10
EP4175620B1 (en) 2024-04-10
WO2023283439A1 (en) 2023-01-12
EP4197528A1 (en) 2023-06-21
TW202317079A (zh) 2023-05-01
WO2023283438A1 (en) 2023-01-12
KR20240042436A (ko) 2024-04-02
EP4366695A1 (en) 2024-05-15
WO2023283441A1 (en) 2023-01-12
KR20240042437A (ko) 2024-04-02
AU2022306682A1 (en) 2024-01-25
EP4175619B1 (en) 2024-04-10
TW202317081A (zh) 2023-05-01
CO2024000742A2 (es) 2024-02-26
FI4197528T3 (fi) 2024-05-24
IL309888A (en) 2024-03-01
EP4197528B1 (en) 2024-04-03
PE20240808A1 (es) 2024-04-18
FI4175619T3 (fi) 2024-05-28
KR20240042438A (ko) 2024-04-02
PE20240807A1 (es) 2024-04-18
DOP2024000005A (es) 2024-04-15
CA3226153A1 (en) 2023-01-12
CO2024000748A2 (es) 2024-02-26
CA3226557A1 (en) 2023-01-12
US20230026203A1 (en) 2023-01-26
IL309907A (en) 2024-03-01
DOP2024000006A (es) 2024-04-15
AU2022305962A1 (en) 2024-01-25
DK4175619T3 (da) 2024-05-06
DOP2024000004A (es) 2024-04-15
TW202317080A (zh) 2023-05-01
CO2024000631A2 (es) 2024-02-15
AU2022308837A1 (en) 2024-01-25
EP4175619A1 (en) 2023-05-10

Similar Documents

Publication Publication Date Title
DK3453707T3 (da) Benzazepinderivat, fremgangsmåde til fremstilling, farmaceutisk sammensætning og anvendelse deraf
DK3681804T3 (da) Systemer og fremgangsmåder til levering, opbevaring og behandling af materialer i rummet
HK1246309A1 (zh) 去免疫化的志賀毒素a亞基支架和包含它們的細胞靶向分子
DK3524603T3 (da) Fgfr4-hæmmer, fremgangsmåde til fremstilling deraf og farmaceutisk anvendelse deraf
DK3313817T3 (da) Bicycliske derivater, fremgansmåde til deres fremstilling og farmaceutiske sammensætninger indeholdende disse
DK3426250T3 (da) Behandling af en patient med et cyp3a4-substratlægemiddel, der er kontraindiceret til administration sammen med en stærk cyp3a4-inhibitor
DK3326615T3 (da) Kontinuerlig indgivelse af l-dopa-, dopa- decarboxylase-inhibitorer, catechol-o-methyltransferaseinhibitorer og sammensætninger til samme
IL275798A (en) Methods for antibody drug conjugation, purification and formulation
DK3319609T3 (da) Sammensætninger og fremgangsmåder til anvendelse af antibakterielle lægemiddelkombinationer
DK3937902T3 (da) Farmaceutisk doseringsform til påføring på slimhinder og fremgangsmåder til fremstilling af denne
DK3278803T3 (da) Fast farmaceutisk doseringsform af PARP-inhibitor, og anvendelse af fast farmaceutisk doseringsform af PARP-inhibitor
DK3744316T3 (da) Oftalmisk farmaceutisk sammensætning, fremgangsmåde til fremstilling deraf og anvendelse deraf
DK3404024T3 (da) Quinazolinonderivat, fremgangsmåde til fremstilling deraf, farmaceutisk sammensætning og anvendelser
DK4175619T3 (da) Sammensætninger, fremgangsmåder og systemer til indgivelse af medicin med aerosol
DK3452001T3 (da) Anordning og fremgangsmåde til emballering af faste lægemidler, anordning til opbevaring og udlevering af sådanne lægemidler og fremgangsmåde til udlevering
DK3275454T3 (da) Farmaceutisk sammensætning med silybin, ve og l-carnitin
ZA202108771B (en) Flavonoid polyphenol drug self-emulsifying composition, preparation method therefor, pharmaceutical composition thereof and application thereof
DK3833682T3 (da) Selvmordsmolekyle sammensætninger og fremgangsmåder
DK3707128T3 (da) Injicerbare, farmaceutiske isoxazolinsammensætninger og anvendelse deraf mod parasitangreb
DK3688147T3 (da) Hidtil ukendt lægemiddelindgivelsessystem og fremgangsmåder til tilvejebringelse heraf
DK3383397T3 (da) Farmaceutiske sammensætninger indeholdende doravirin, tenofovirdisoproxilfumarat og lamivudin
SG11202102742RA (en) Cyclic dinucleotide analogue, pharmaceutical composition thereof, and application
IL287920A (en) Antigen binding molecule, pharmaceutical composition, and method
DK3285835T3 (da) Doseringsapparat og anordning til indgivelse af medicin
DK3373996T3 (da) Fremgangsmåde til frembringelse, anvendelse og administration af aktiverede stamceller